• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

How Wal­greens plans to re­vive re­tail phar­ma­cy with­in three years

9 months ago
Health Tech

Dig­i­tal health start­up Sesame starts of­fer­ing com­pound­ed weight loss shots

9 months ago
Startups
Health Tech

Ver­sant and No­var­tis build 'Chi­nook 2.0' for RNA ther­a­pies in kid­ney dis­eases

9 months ago
Financing
Startups

Bio­gen, Ei­sai’s Leqem­bi wins UK ap­proval, but not im­me­di­ate NHS cov­er­age

9 months ago
Pharma

Up­dat­ed: Chi­nese gov­ern­ment in­dicts Japan­ese Astel­las em­ploy­ee for es­pi­onage

9 months ago
People
China

FDA warns hos­pi­tals against us­ing Pfiz­er's re­main­ing potas­si­um in­jec­tions for chil­dren

9 months ago
Pharma
FDA+

Bio­Marin shakes up ex­ec­u­tive team, tap­ping no­table deal­mak­er James Sabry

9 months ago
People
Pharma

WuXi Bio spot­lights new US con­tracts, but prof­its are down as Biose­cure brews

9 months ago
China
Manufacturing

Tim­ber Phar­ma­ceu­ti­cal­s' can­di­date for rare skin dis­or­der flunks all end­points in late-stage tri­al

9 months ago
R&D

In­di­an CD­MOs un­like­ly to see sud­den surge in clients if Chi­na bill pass­es, ex­ecs say 

9 months ago
China
Manufacturing

FDA re­jects Re­gen­eron’s mul­ti­ple myelo­ma bis­pe­cif­ic an­ti­body over man­u­fac­tur­ing is­sues

9 months ago
R&D
Manufacturing

Van­dria rais­es an­oth­er $10M; Nykode ends Phase 2 tri­al in cer­vi­cal can­cer

9 months ago
News Briefing

Bridge­Bio forms an­oth­er off­shoot with $300M in com­mit­ments

9 months ago
Financing
Startups

Dr. Red­dy's and Stan­ford spin­out Kain­o­myx part­ner up on an­ti-malar­i­al pro­gram

9 months ago
Deals
R&D

Aa­di says its sol­id tu­mor drug is un­like­ly to suc­ceed, wind­ing down the tri­al and ax­ing staffers

9 months ago
People
R&D

Af­ter Pfiz­er lay­offs, Ar­ray chemists re­gath­er at next-gen obe­si­ty biotech Am­brosia Bio­sciences

9 months ago
Financing
Startups

Semaglu­tide may come with a high­er risk of sui­ci­dal thoughts, JA­MA study finds

9 months ago
Pharma

WuXi Bi­o­log­ics’ ADC spin­out re­ports rev­enue jump de­spite Biose­cure risk

9 months ago
China
Manufacturing

J&J scores ap­proval for Ry­bre­vant com­bo in first-line lung can­cer, stok­ing ri­val­ry with Tagris­so

9 months ago
Pharma
FDA+

Law­suit al­leges Bio­gen schemed with PBMs to pre­serve Tec­fidera mar­ket

9 months ago
Law

FTC backs FDA plan to re­move switch­ing study re­quire­ment for in­ter­change­able biosim­i­lars

9 months ago
FDA+

Emer­gent joins broad­er ef­forts for mpox vac­cine dri­ve in Africa

9 months ago
Pharma
Manufacturing

House law­mak­ers call on FDA to in­ves­ti­gate clin­i­cal tri­als run along­side Chi­na's mil­i­tary

9 months ago
China
FDA+

Kymera seeks to raise $225M; Ad­cen­do, Mul­ti­tude's new ADC deal

9 months ago
News Briefing
First page Previous page 114115116117118119120 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times